FDA head calls for probe into Alzheimer’s drug review
WASHINGTON — The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between some of her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.